Feasibility Study of Yuejuwan as an Adjuvant Therapy for Primary Liver Cancer

Abstract

Primary liver cancer is one of the common malignant tumours of the digestive system in clinical practice, and in the modern healthcare system, the therapeutic efficacy of primary liver cancer and the quality of patients' survival have always been the focus of medical research. In the face of this challenge, traditional Chinese medicine (TCM) offers unique perspectives and potential solutions, among which Yuejuwan, as a traditional Chinese medicine prescription with a long history, has attracted widespread attention for its application value in the treatment of primary liver cancer. This paper discusses and analyses the treatment of primary liver cancer in terms of the etiology and pathogenesis of liver cancer, the types of evidence, as well as the rationale and prescription of Yuejuwan, and the study of its pharmacological effects, aiming at exploring the feasibility of Yuejuwan as an adjuvant therapy in the treatment of primary liver cancer and its mechanism of action. It provides a new understanding of the identification and treatment of primary liver cancer, in order to improve the clinical efficacy of primary liver cancer, and to achieve the purpose of alleviating the pain of patients and improving the quality of their survival.